1.
Ugeskr Laeger
; 175(37): 2090-3, 2013 Sep 09.
Artigo
em Dinamarquês
| MEDLINE
| ID: mdl-24011203
RESUMO
In clinical trials a single dose of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has shown a rapid antidepressant effect in patients with treatment-resistant depression and bipolar depression. The implications of glutaminergic mechanisms in depression and the rapid effect of a single dose of ketamine could open new pathways to understand the pathophysiology of depression and the development of novel rapid-acting antidepressant drugs.